ライフサイエンスコーパス: haemorrhagic

1 80% of strokes are ischaemic, as opposed to haemorrhagic.

2 Although traumatic and haemorrhagic acute brain injury are generally considered

3 MRI detected acute stroke (ischaemic or haemorrhagic), acute ischaemic stroke, and chronic haemo

4 er alone or in combination: grade 3 or worse haemorrhagic adverse events; platelet counts of less tha

5 tion of these venom components to the severe haemorrhagic and coagulopathic pathology of envenoming a

6 y emphasise the counter-balancing effects of haemorrhagic and ischaemic complications after stent imp

7 ripheral vessel AVMs, stroke (separately for haemorrhagic and ischaemic), transient ischaemic attack

8 In post-haemorrhagic and other forms of communicating hydrocepha

9 total cholesterol was negatively related to haemorrhagic and total stroke mortality.

10 zations occur spontaneously after ischaemic, haemorrhagic and traumatic brain injury.

11 fatal stroke, and death from cardiovascular, haemorrhagic, and unknown causes (Antiplatelet Trialists

12 ions, increased NCAM expression and produced haemorrhagic angiogenesis in mouse matrigel implants.

13 ith OCCC-like histopathology, culminating in haemorrhagic ascites and a median survival period of 7.5

14 verity of any recurrent stroke (ischaemic or haemorrhagic; assessed using the modified Rankin Scale)

15 n in central blood volume during a simulated haemorrhagic challenge combined with heat stress.

16 in regional blood volumes during a simulated haemorrhagic challenge imposed via lower-body negative p

17 ons in the capacity to withstand a simulated haemorrhagic challenge; however, this capacity is normal

18 Escherichia coli O157:H7 causes diarrhoea, haemorrhagic colitis, and the haemolytic uraemic syndrom

19 asymptomatic shedding, non-bloody diarrhoea, haemorrhagic colitis, haemolytic uraemic syndrome, and d

20 EC) serotype O157:H7, the causative agent of haemorrhagic colitis, has been shown to utilize a cell-t

21 and has been implicated in many outbreaks of haemorrhagic colitis, some of which included fatalities

22 erapeutic for the treatment of juvenile post-haemorrhagic communicating hydrocephalus.

23 ad substantially lower 30-day rates of major haemorrhagic complications and net adverse clinical even

24 ile significantly lowering the risk of major haemorrhagic complications.

25 ogenic oedema, and catastrophic failure with haemorrhagic conversion.

26 sfunction, resulting in oedema formation and haemorrhagic conversion.

27 topenia (BNP; previously known as idiopathic haemorrhagic diathesis and commonly known as bleeding ca

28 ation when applied to specific cases--rabbit haemorrhagic disease and fox rabies.

29 ly identified viruses associated with severe haemorrhagic disease in humans in China and the US.

30 known as bleeding calf syndrome) is a novel haemorrhagic disease of young calves which has emerged i

31 Recently, a new variant of the rabbit haemorrhagic disease virus (RHDV2 or RHDVb) arguably cau

32 Haemorrhagic disease, encephalitis, biphasic fever, flac

33 r research on the pathogenesis of nairoviral haemorrhagic disease.

34 Haemophilia A and B are hereditary haemorrhagic disorders characterised by deficiency or dy

35 ding anaemia, malignant blood disorders, and haemorrhagic disorders.

36 trolling excessive bleeding in patients with haemorrhagic disorders.

37 io 0.51; 95% CI 0.31-0.85) but not for major haemorrhagic events (0.88, 0.74-1.06) or death (0.82, 0.

38 vein thrombosis, or pulmonary embolism) and haemorrhagic events (symptomatic intracranial or signifi

39 ation had a high risk of both thrombotic and haemorrhagic events after stroke.

40 r risk of thrombotic events or lower risk of haemorrhagic events benefited from heparins.

41 led in the MATRIX-Access (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Syste

42 sub-study of the MATRIX (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Syste

43 (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Syste

44 c events was 0.63 (95% CI 0.59-0.67) and for haemorrhagic events was 0.60 (0.55-0.64).

45 uartiles of predicted risk of thrombotic and haemorrhagic events with random effect meta-analysis.

46 of venous thrombotic events or a low risk of haemorrhagic events.

47 k of thrombotic events or decreasing risk of haemorrhagic events.

48 Some infections result in dengue haemorrhagic fever (DHF), a syndrome that in its most se

49 life-threatening form of the disease, dengue haemorrhagic fever (DHF).

50 at TfR1 is a cellular receptor for New World haemorrhagic fever arenaviruses.

51 Outbreaks of haemorrhagic fever caused by the Ebola virus are associa

52 underlying the potential of widespread viral haemorrhagic fever epidemics.

53 nd Marburg filoviruses cause a rapidly fatal haemorrhagic fever in humans for which no approved antiv

54 g Zaire ebolavirus (ZEBOV), can cause lethal haemorrhagic fever in humans.

55 e causative agents of a severe form of viral haemorrhagic fever in man, designated Ebola haemorrhagic

56 Furthermore, Ebola haemorrhagic fever is currently spreading through ape po

57 indow into the evolution of an ongoing viral haemorrhagic fever outbreak.

58 vary within Africa, with regions where viral haemorrhagic fever outbreaks have previously occurred (e

59 We used a rhesus macaque model of MARV haemorrhagic fever that produced 100% lethality.

60 resembling that observed with Crimean-Congo Haemorrhagic Fever virus in humans.

61 ses like Rift Valley fever and Crimean-Congo haemorrhagic fever viruses continue to emerge in new geo

62 arito, Junin and Sabia viruses are New World haemorrhagic fever viruses that do not use alpha-dystrog

63 of tick-borne encephalitis and Crimean-Congo haemorrhagic fever viruses, have changed their geographi

64 us, idiopathic pulmonary fibrosis and dengue haemorrhagic fever).

65 haemorrhagic fever in man, designated Ebola haemorrhagic fever, and are endemic in regions of centra

66 haemorrhagic fevers in Africa, Crimean-Congo haemorrhagic fever, Ebola virus disease, Lassa fever, an

67 We used a rhesus macaque model of Ebola haemorrhagic fever, which produces near 100% mortality.

68 s a model for the treatment of ZEBOV-induced haemorrhagic fever.

69 rmly lethal non-human primate model of ZEBOV haemorrhagic fever.

70 ephalitis, Kyasanur Forest disease, and Omsk haemorrhagic fever.

71 rovides a paradigm for the treatment of MARV haemorrhagic fever.

72 loped clinical symptoms consistent with MARV haemorrhagic fever.

73 respiratory syndrome), avian influenza, and haemorrhagic fever.

74 (rVSV), as a postexposure treatment for MARV haemorrhagic fever.

75 athway could ameliorate the effects of Ebola haemorrhagic fever.

76 s: filamentous, enveloped viruses that cause haemorrhagic fever.

77 ging pathogens and causative agents of viral haemorrhagic fever.

78 usly efficient vectors of malaria and Dengue haemorrhagic fever.

79 arburg filoviruses cause deadly outbreaks of haemorrhagic fever.

80 ubnational pandemic potential for four viral haemorrhagic fevers in Africa, Crimean-Congo haemorrhagi

81 At least five arenaviruses cause viral haemorrhagic fevers in humans.

82 onse syndromes in bacterial sepsis and viral haemorrhagic fevers, and anticoagulants can be effective

83 lance and response capacity to contain viral haemorrhagic fevers.

84 stream regulator of Yap that can cause fetal haemorrhagic hydrocephalus, deregulates Yap in the devel

85 ral CB1 cannabinoid receptors contributes to haemorrhagic hypotension, and anandamide produced by mac

86 and cortical superficial siderosis-a new CAA haemorrhagic imaging signature and (b) whether acute cSA

87 plications (one cerebral haemorrhage and one haemorrhagic infarct) directly related to surgery.

88 in 88 (29.3%) patients, among which 62 were haemorrhagic infarction and 26 were parenchymal haemorrh

89 al haemorrhage occur after the initial acute haemorrhagic insult subsides, and represent one of its m

90 was fatal or disabling stroke (ischaemic or haemorrhagic), intracranial haemorrhage, or clinically s

91 y with prolonged bleeding and progression of haemorrhagic lesions, the risk of hypercoagulopathy with

92 rosis and other white-matter diseases (acute haemorrhagic leucoencephalitis, leucodystrophies and cen

93 a severe multisystem disease that often has haemorrhagic manifestations.

94 Immediate haemorrhagic mortality constitutes the largest group of

95 bsequent collapse of tumours, similar to non-haemorrhagic necrosis in ischaemia and unlike haemorrhag

96 aemorrhagic necrosis in ischaemia and unlike haemorrhagic necrosis induced by tumour necrosis factor.

97 e mice die from hepatocellular apoptosis and haemorrhagic necrosis.

98 Since type C isolates cause both haemorrhagic necrotic enteritis and fatal enterotoxemias

99 getative cultures of wild-type CN3685 caused haemorrhagic necrotizing enteritis in rabbit ileal loops

100 2 QS system, is required for CN3685 to cause haemorrhagic necrotizing enteritis, apparently because t

101 images results in the detection of more 'non-haemorrhagic' pathology.

102 incidence of childhood stroke (ischaemic and haemorrhagic) range from 2.3 to 13.0 per 100,000 childre

103 The classic features of haemorrhagic rash, meningism, and impaired consciousness

104 ons for fatal rather than non-fatal, and for haemorrhagic rather than ischaemic stroke.

105 The haemorrhagic risks of the combination of aspirin and clo

106 t late seizure following an immediately post-haemorrhagic seizure; and (ii) investigate the effect of

107 olar epithelium in the early phase following haemorrhagic shock by attenuating NO-mediated oxidative

108 ort across the alveolar epithelium following haemorrhagic shock is mediated by reactive nitrogen spec

109 We treated a 2.9 kg neonate with haemorrhagic shock, multiple organ dysfunction, and seve

110 rease in blood pressure in rats subjected to haemorrhagic shock, whereas similar treatment of normote

111 further in clinical settings, especially for haemorrhagic states.

112 ; p<0.0001), mainly driven by a reduction in haemorrhagic stroke (0.49, 0.38-0.64; p<0.0001).

113 and there were significant reductions in non-haemorrhagic stroke (131 [2.8%] vs 174 [3.8%]; RR 0.75,

114 number of people with incident ischaemic and haemorrhagic stroke (37% and 47% increase, respectively)

115 rterial ischaemic stroke (AIS) and 43 with a haemorrhagic stroke (HS) were identified.

116 significant (0.20%vs 0.21% per year, p=0.4: haemorrhagic stroke 0.04%vs 0.03%, p=0.05; other stroke

117 tated regimens than in primary intervention (haemorrhagic stroke 15 [0.7%] vs two [0.1%], p=0.0014; t

118 Haemorrhagic stroke accounts for approximately 20% of st

119 icant increase of 22% (5-30) in incidence of haemorrhagic stroke and a 6% (-7 to 18) non-significant

120 Haemorrhagic stroke and total stroke rates were higher i

121 amyloid angiopathy, an untreatable cause of haemorrhagic stroke and vascular cognitive impairment.

122 <0.0001), with a non-significant increase in haemorrhagic stroke but reductions of about a fifth in t

123 regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010.

124 mortality data suggest that the incidence of haemorrhagic stroke has fallen in the past 20 years, but

125 andardised mortality rates for ischaemic and haemorrhagic stroke have decreased in the past two decad

126 For haemorrhagic stroke in low-income and middle-income coun

127 country-specific estimates for ischaemic and haemorrhagic stroke incidence, mortality, mortality-to-i

128 Worldwide, the burden of ischaemic and haemorrhagic stroke increased significantly between 1990

129 The burden of ischaemic and haemorrhagic stroke varies between regions and over time

130 eg, neuroprotective drugs and treatments for haemorrhagic stroke) options in the prehospital setting,

131 ity, myocardial infarction, and ischaemic or haemorrhagic stroke), hospital events for heart failure

132 d systemic embolic events, ischaemic stroke, haemorrhagic stroke, all-cause mortality, myocardial inf

133 management, reversal of warfarin effects in haemorrhagic stroke, and management of cerebral emergenc

134 tients had CNS events (six ischaemic and one haemorrhagic stroke, eight transient ischaemic attacks,

135 For haemorrhagic stroke, incidence reduced significantly by

136 myocardial infarction or coronary death, non-haemorrhagic stroke, or any arterial revascularisation p

137 wo persons had severe amyloid angiopathy and haemorrhagic stroke.

138 amyloid angiopathy is an important cause of haemorrhagic stroke.

139 cant protective effect on both ischaemic and haemorrhagic stroke.

140 new-onset diabetes mellitus, and, probably, haemorrhagic stroke.

141 c options for collagen IV diseases including haemorrhagic stroke.

142 ) for ischaemic stroke; 1.56 (1.19-2.05) for haemorrhagic stroke; 1.84 (1.59-2.13) for unclassified s

143 nts aged 18-83 years with ischaemic (ie, non-haemorrhagic) stroke with a baseline National Institutes

144 e were no apparent differences in numbers of haemorrhagic strokes (24 [0.4%] vs 25 [0.4%]) or deaths

145 n encountered in patients with ischaemic and haemorrhagic strokes, subarachnoid haemorrhage, cerebrov

146 sis), 50-100 new cases of diabetes, and 5-10 haemorrhagic strokes.

147 ortion of ischaemic strokes and a decline in haemorrhagic strokes.

148 Hereditary haemorrhagic telangiectasia (HHT) [corrected] is a vascu

149 enesis and has been implicated in hereditary haemorrhagic telangiectasia (HHT), atherosclerosis, tumo

150 es on a human vascular dysplasia, hereditary haemorrhagic telangiectasia (HHT), wherein arterial and

151 Juvenile polyposis and hereditary haemorrhagic telangiectasia are autosomal dominant disor

152 ng of both juvenile polyposis and hereditary haemorrhagic telangiectasia phenotypes.

153 gene with the inherited disorder Hereditary Haemorrhagic Telangiectasia Type 1 (HHT1), a disease cha

154 mutations in the ALK1 gene cause hereditary haemorrhagic telangiectasia type 2 (HHT2), a disabling d

155 vascular lesions associated with hereditary haemorrhagic telangiectasia, especially occult arteriove

156 Hereditary haemorrhagic telangiectasia, or Osler-Rendu-Weber (ORW)

157 lmonary arterial hypertension and hereditary haemorrhagic telangiectasia.

158 n in smooth muscle that occurs in hereditary haemorrhagic telangiectasia.

159 In a mouse model of CAA there is a low haemorrhagic threshold after thrombolytic therapy compar

160 Thrombolysis-related haemorrhagic transformation (HT) subtypes may have diffe

161 Complications of rt-PA therapy, such as haemorrhagic transformation and angio-oedema, are review

162 administration of tPA (10 mg/kg) resulted in haemorrhagic transformation in the ischaemic territory 1

163 ilable to rescue ischaemic brain tissue; the haemorrhagic transformation that can cause severe functi

164 ter delayed tPA treatment in ischaemic mice, haemorrhagic transformation was significantly decreased,

165 l venous thrombosis, head trauma, or tumour; haemorrhagic transformation within an infarct; and refer

166 gical complications, such as brain oedema or haemorrhagic transformation, occur earlier than do medic

167 wn after ischaemic stroke and lead to lethal haemorrhagic transformation.

168 gulatory T cell transfer against tPA-induced haemorrhagic transformation.

169 e increased cerebrovascular permeability and haemorrhagic transformation.

170 e clearest association was with the familial haemorrhagic variant where all four families tested had

171 oke was subdivided into fatal, ischaemic and haemorrhagic, with higher magnitude associations for fat

172 mary outcome was total stroke (ischaemic and haemorrhagic) within 90 days.